REMARKS

AMENDMENTS TO THE CLAIMS:

Claims 32 and 34 have been amended. Claims 30 to 49 are pending.

Claim 32 has been amended to change SEQ ID NO:3 to SEQ ID NO:2 (specifically "3" was changed to "2") to correctly identify the polynucleotide sequence, in this case SEQ ID NO:2, that encodes the polypeptide sequence provided as SEQ ID NO:4. Support for this amendment is provided in Figures 2A-C, Figure 4, original Claim 13, the Sequence Listing as originally submitted, and throughout the specification as originally filed. No new matter has been added.

Claim 34 has been amended to change SEQ ID NO:3 to SEQ ID NO:2 (specifically "3" was changed to "2") to correctly identify the polynucleotide sequence, in this case SEQ ID NO:2, that encodes the polypeptide sequence provided as SEQ ID NO:4. Support for this amendment is provided in Figures 2A-C, Figure 4, original Claim 13, the Sequence Listing as originally submitted, and throughout the specification as originally filed. No new matter has been added.

NO.549 P.6

I. Miscellaneous

a. Restriction Requirement

Applicants spoke with the Examiner regarding the discrepancy between the SEQ ID NOs elected in Applicants September 17th, 2003 Reply to the Restriction Requirement, mailed August 18, 2003, and the sequences listed in the Sequence Listing of the instant specification, on June 17th, 2004. Applicants acknowledged this discrepancy and indicated via telephone to the Examiner that the polynucleotide embraced by SEQ ID NO:2 that encodes the polypeptide of SEQ ID NO:4 comprised the basis of Applicants election. The present amendment corrects this discrepancy by changing the prior reference to SEQ ID NO:3 to the correct reference of SEQ ID NO:2 in Claims 32 and 34.

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: June 17, 2004

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652